ChemoSeed is a bioresorbable implant to provide a drug delivery system for the treatment of tumours, whilst avoiding the unwanted side effects associated with current treatments.
Constructed from a polylactic-co-glycolic acid polymer, each ChemoSeed measures 6mm in length and 2mm in diameter. In its first indication, high grade glioma (HGG), the number of seeds implanted is estimated to range from 15 to 45 depending on the tumour resection size and cavity. The seeds are implanted through a 12-gauge biopsy needle or catheter, with each seed designed to dispense the drug for a minimum of seven days, and potentially extending up to 35 days.
Administering ChemoSeeds during surgery requires minimal additional time (estimated at approximately 40 minutes) to current resection procedures. ChemoSeeds have been designed to remain at the implantation site within the tumour or resection margin. This has been evaluated in a 0.6 per cent. agarose gel model, which has similar properties as brain tissue, where all seeds remained in place.
Each seed biodegrades over three to six months, and are fully degraded before the first MRI post surgery and any subsequent resection surgeries. ChemoSeeds can also be multilayered, facilitating the delivery of multiple drugs, thereby enabling personalised drug combinations and dosages tailed to individual patients’ needs. The Directors believe that ChemoSeed is a platform drug delivery technology that will allow the development of novel therapies and the re-purposing/formulation of regulatory approved drugs.
Based on recent successful projects CRISM Therapeutics have patented and trade marked the ChemoSeed process for delivery of re-purposed and novel drugs.
Comments